Related Experiment Videos
[Bone marrow transplantation for lysosomal storage diseases]
1Department of Pediatrics, Tohoku University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 1, 1995
Summary
Bone marrow transplantation (BMT) treats lysosomal storage diseases, improving physical symptoms but with variable neurological outcomes. Further studies are needed to understand BMT
Area of Science:
- Biomedical research
- Hematology
- Genetics
Context:
- Bone marrow transplantation (BMT) is an established treatment for lysosomal storage diseases (LSDs) since 1981.
- While BMT improves somatic symptoms in LSDs, neurological and cognitive outcomes remain highly variable.
- Understanding enzyme transfer to the central nervous system (CNS) is crucial for predicting BMT efficacy.
Purpose:
- To review the current understanding of BMT for LSDs.
- To highlight the factors influencing therapeutic outcomes.
- To emphasize the need for long-term clinical and biochemical follow-up studies.
Summary:
- BMT offers a potential treatment for LSDs, including Hurler's disease, mucopolysaccharidosis, and lipidosis.
- Neurologic and intelligence outcomes post-BMT are inconsistent, necessitating further investigation into CNS engraftment.
- Factors such as biochemical correction, tissue reversibility, and disease stage impact long-term BMT effectiveness.
Impact:
- Informs clinicians and researchers on the complexities of BMT for LSDs.
- Guides future research directions for improving BMT efficacy and predicting patient outcomes.
- Contributes to a better understanding of the long-term consequences and therapeutic potential of BMT in genetic metabolic disorders.